Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma

NCT04385277 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT04385277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04385277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma
Lead sponsor
Children's Oncology Group
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 31, 2020
Completion date
September 30, 2027
Enrollment
41 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

ganglioneuroblastoma, nodular, neuroblastoma